Financials Hanmi Science Co., Ltd.

Equities

A008930

KR7008930000

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-05-02 pm EDT 5-day change 1st Jan Change
33,550 KRW -1.03% Intraday chart for Hanmi Science Co., Ltd. +0.75% -14.41%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5,010,439 2,480,585 5,020,056 3,646,182 2,206,472 2,664,917
Enterprise Value (EV) 1 5,003,581 2,508,896 5,056,459 3,686,047 2,386,962 2,844,145
P/E ratio 278 x 80.7 x 222 x 84.9 x 32.1 x 23.1 x
Yield 0.25% 0.52% 0.26% 0.36% 0.62% 0.51%
Capitalization / Revenue 7.08 x 3.04 x 5.86 x 3.84 x 2.11 x 2.14 x
EV / Revenue 7.07 x 3.07 x 5.9 x 3.88 x 2.28 x 2.28 x
EV / EBITDA 321 x 111 x 161 x 108 x 71.1 x 43.3 x
EV / FCF 1,966 x 364 x 544 x 682 x -132 x 62.5 x
FCF Yield 0.05% 0.27% 0.18% 0.15% -0.76% 1.6%
Price to Book 7.52 x 3.84 x 7.62 x 5.28 x 3.04 x 3.37 x
Nbr of stocks (in thousands) 68,651 68,642 68,632 68,618 67,996 67,983
Reference price 2 72,984 36,138 73,145 53,137 32,450 39,200
Announcement Date 3/7/19 3/12/20 3/18/21 3/16/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 707,995 816,619 857,383 950,165 1,046,054 1,247,906
EBITDA 1 15,602 22,520 31,360 34,009 33,590 65,744
EBIT 1 10,997 16,145 25,152 28,753 28,112 57,012
Operating Margin 1.55% 1.98% 2.93% 3.03% 2.69% 4.57%
Earnings before Tax (EBT) 1 18,820 35,432 29,966 49,122 73,180 130,542
Net income 1 18,020 30,742 22,601 42,942 69,210 115,122
Net margin 2.55% 3.76% 2.64% 4.52% 6.62% 9.23%
EPS 2 262.8 447.9 329.3 625.8 1,010 1,694
Free Cash Flow 1 2,545 6,891 9,297 5,406 -18,030 45,486
FCF margin 0.36% 0.84% 1.08% 0.57% -1.72% 3.64%
FCF Conversion (EBITDA) 16.31% 30.6% 29.65% 15.9% - 69.19%
FCF Conversion (Net income) 14.12% 22.42% 41.14% 12.59% - 39.51%
Dividend per Share 2 184.8 188.5 188.5 192.2 200.0 200.0
Announcement Date 3/7/19 3/12/20 3/18/21 3/16/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 28,311 36,403 39,865 180,489 179,228
Net Cash position 1 6,858 - - - - -
Leverage (Debt/EBITDA) - 1.257 x 1.161 x 1.172 x 5.373 x 2.726 x
Free Cash Flow 1 2,545 6,891 9,297 5,406 -18,030 45,486
ROE (net income / shareholders' equity) 2.73% 4.73% 3.46% 6.37% 9.76% 15.1%
ROA (Net income/ Total Assets) 0.74% 1.1% 1.71% 1.92% 1.71% 3.05%
Assets 1 2,432,441 2,783,813 1,318,463 2,238,078 4,056,596 3,773,362
Book Value Per Share 2 9,703 9,407 9,598 10,060 10,659 11,621
Cash Flow per Share 2 399.0 244.0 216.0 242.0 315.0 407.0
Capex 1 770 1,253 958 1,816 7,398 6,930
Capex / Sales 0.11% 0.15% 0.11% 0.19% 0.71% 0.56%
Announcement Date 3/7/19 3/12/20 3/18/21 3/16/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. A008930 Stock
  4. Financials Hanmi Science Co., Ltd.